GlassScriptPhysician profile
Jerald Hershman
NPI 1699783019
$758.09
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $260 · 2022: $29.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $133.37 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $129.40 | 2019-2020 | |
| Novo Nordisk INC | $108.61 | 2019-2020 | |
| Lilly USA, LLC | $83.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.60 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.74 | 2019 | |
| Genentech USA, INC. | $39.50 | 2019-2020 | |
| Abbvie INC. | $29.39 | 2022 | |
| Amarin Pharma, INC. | $29.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.67 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $24.64 | 2019 | |
| Pfizer INC. | $15.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.73 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerald Hershman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.